EMPAGLIFLOZIN AND LINAGLIPTIN
Clinical safety rating: safe
No significant drug interactions May cause hypersensitivity reactions including anaphylaxis.
Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormones (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon levels.
| Metabolism | Empagliflozin: primarily glucuronidation by UGT2B7, UGT1A3, UGT1A8, and UGT1A9. Linagliptin: primarily enterohepatic recirculation with minimal hepatic metabolism; metabolized by CYP3A4 to a minor extent. |
| Excretion | Empagliflozin: 54% excreted unchanged in urine (renal), 41% in feces (biliary/fecal). Linagliptin: 80% excreted unchanged in feces via enterohepatic circulation, <5% in urine. |
| Half-life | Empagliflozin: terminal half-life ~12.4 hours, allowing once-daily dosing. Linagliptin: terminal half-life ~113-131 hours due to saturable binding to DPP-4, enabling once-daily dosing despite short plasma half-life. |
| Protein binding | Empagliflozin: 86.2% bound primarily to plasma proteins (albumin). Linagliptin: 70-89% bound; concentration-dependent, mainly to albumin. |
| Volume of Distribution | Empagliflozin: Vd ~38 L (0.5-0.6 L/kg), reflecting moderate tissue distribution. Linagliptin: Vd ~1,040 L (15 L/kg), indicating extensive tissue binding (e.g., DPP-4 enzyme). |
| Bioavailability | Empagliflozin: oral bioavailability ~78% in therapeutic range, decreased with high-fat meal; no dose adjustment. Linagliptin: oral bioavailability ~30% due to presystemic metabolism; food decreases Cmax but not AUC. |
| Onset of Action | Empagliflozin: ~1-2 hours after oral dose (glycosuria onset). Linagliptin: DPP-4 inhibition >80% within 30 minutes, peak inhibition at 1-2 hours. |
| Duration of Action | Empagliflozin: 24 hours due to once-daily dosing; sustained glycosuria throughout. Linagliptin: >24 hours due to long receptor binding; DPP-4 inhibition maintained >80% at 24 hours. |
10 mg empagliflozin / 5 mg linagliptin orally once daily
| Dosage form | TABLET |
| Renal impairment | eGFR ≥45 mL/min/1.73m2: no adjustment. eGFR 30-44: contraindicated (empagliflozin labeled for use, but renal efficacy not established; linagliptin no adjustment). eGFR <30: contraindicated (empagliflozin); linagliptin no adjustment but caution. Empagliflozin not recommended if on dialysis. |
| Liver impairment | Child-Pugh A, B, C: no adjustment required for empagliflozin or linagliptin. However, experience in severe hepatic impairment is limited. |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years. |
| Geriatric use | No specific dose adjustment based on age alone. Monitor renal function regularly; consider risk of volume depletion and hypotension with empagliflozin in elderly patients. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions May cause hypersensitivity reactions including anaphylaxis.
| FDA category | Animal |
| Breastfeeding | Empagliflozin: Unknown if excreted in human milk; risk to infant not excluded. Linagliptin: Excreted in rat milk; unknown in humans. M/P ratio not available. Breastfeeding is not recommended during therapy. |
| Teratogenic Risk | Empagliflozin: Limited human data; animal studies show renal toxicity in developing kidneys. Risk cannot be excluded. Linagliptin: No evidence of teratogenicity in animal studies; limited human data. Both drugs are not recommended during pregnancy, especially in the second and third trimesters due to potential fetal renal effects. |
■ FDA Black Box Warning
None.
| Common Effects | Nasopharyngitis |
| Serious Effects |
["Hypersensitivity to empagliflozin, linagliptin, or any component","History of serious hypersensitivity reaction (e.g., anaphylaxis, angioedema) to either component","Type 1 diabetes mellitus","Diabetic ketoacidosis","Severe renal impairment (eGFR < 30 mL/min/1.73 m2)","End-stage renal disease or dialysis"]
| Precautions | ["Pancreatitis (reported with DPP-4 inhibitors)","Heart failure (reported with DPP-4 inhibitors)","Hypoglycemia (especially when used with insulin or sulfonylureas)","Genital mycotic infections","Urinary tract infections","Volume depletion/hypotension (especially in elderly, renal impairment, or diuretic use)","Acute kidney injury","Ketoacidosis (including euglycemic ketoacidosis)","Lower limb amputation (associated with SGLT2 inhibitors)","Necrotizing fasciitis of the perineum (Fournier's gangrene)","Severe and disabling arthralgia (reported with DPP-4 inhibitors)"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose, renal function (serum creatinine, eGFR), volume status, and blood pressure. Fetal monitoring includes ultrasound for growth and amniotic fluid volume (due to SGLT2 inhibitor risk of oligohydramnios). |
| Fertility Effects | Empagliflozin: No human data; animal studies show no impairment of fertility. Linagliptin: No human data; animal studies show no adverse fertility effects. Overall, no expected impact on human fertility. |
| Food/Dietary | No significant food interactions. Acutely reduce alcohol consumption due to possible increased risk of ketoacidosis. |
| Clinical Pearls | Empagliflozin/linagliptin is a fixed-dose combination for type 2 diabetes. Assess renal function before initiation; empagliflozin is not recommended if eGFR <30 mL/min/1.73 m². Monitor for signs of ketoacidosis, even with normal glucose (euglycemic DKA). Linagliptin requires no dose adjustment for renal impairment. Use caution with loop diuretics due to volume depletion risk. Discontinue at time of surgery or during acute illness. |
| Patient Advice | Take once daily with or without food, preferably in the morning. · Stay adequately hydrated to prevent dehydration. · Report symptoms of genital yeast infections, urinary tract infections, or ketoacidosis (nausea, vomiting, abdominal pain, confusion, unusual fatigue). · Monitor blood glucose regularly. · Do not use during pregnancy or breastfeeding. · Inform healthcare providers of all medications, especially diuretics or insulin. · Seek immediate medical attention for difficulty breathing or swelling of face/lips/tongue. |